These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37881436)

  • 1. Immunological analysis of hybrid neoantigen peptide encompassing class I/II neoepitope-pulsed dendritic cell vaccine.
    Morisaki S; Onishi H; Morisaki T; Kubo M; Umebayashi M; Tanaka H; Koya N; Nakagawa S; Tsujimura K; Yoshimura S; Yew PY; Kiyotani K; Nakamura Y; Nakamura M; Kitazono T; Morisaki T
    Front Immunol; 2023; 14():1223331. PubMed ID: 37881436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites.
    Morisaki T; Hikichi T; Onishi H; Morisaki T; Kubo M; Hirano T; Yoshimura S; Kiyotani K; Nakamura Y
    Immunol Invest; 2021 Jul; 50(5):562-579. PubMed ID: 32660279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Intranodal Neoantigen Peptide-pulsed Dendritic Cell Vaccine Monotherapy in Patients With Advanced Solid Tumors: A Retrospective Analysis.
    Morisaki T; Morisaki T; Kubo M; Onishi H; Hirano T; Morisaki S; Eto M; Monji K; Takeuchi A; Nakagawa S; Tanaka H; Koya N; Umebayashi M; Tsujimura K; Yew PY; Yoshimura S; Kiyotani K; Nakamura Y
    Anticancer Res; 2021 Aug; 41(8):4101-4115. PubMed ID: 34281881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of pre-existing neoantigen-specific T cells to a durable complete response after tumor-pulsed dendritic cell vaccine plus nivolumab therapy in a patient with metastatic salivary duct carcinoma.
    Ichimiya S; Fujimura A; Masuda M; Masuda S; Yasumatsu R; Umebayashi M; Tanaka H; Koya N; Nakagawa S; Yew PY; Yoshimura S; Onishi H; Nakamura M; Nakamura Y; Morisaki T
    Immunol Invest; 2022 Jul; 51(5):1498-1514. PubMed ID: 34486463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.
    Linette GP; Becker-Hapak M; Skidmore ZL; Baroja ML; Xu C; Hundal J; Spencer DH; Fu W; Cummins C; Robnett M; Kaabinejadian S; Hildebrand WH; Magrini V; Demeter R; Krupnick AS; Griffith OL; Griffith M; Mardis ER; Carreno BM
    Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23662-23670. PubMed ID: 31685621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models.
    Zhang R; Yuan F; Shu Y; Tian Y; Zhou B; Yi L; Zhang X; Ding Z; Xu H; Yang L
    Cancer Immunol Immunother; 2020 Jan; 69(1):135-145. PubMed ID: 31807878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs.
    Aloysius MM; Mc Kechnie AJ; Robins RA; Verma C; Eremin JM; Farzaneh F; Habib NA; Bhalla J; Hardwick NR; Satthaporn S; Sreenivasan T; El-Sheemy M; Eremin O
    J Transl Med; 2009 Mar; 7():18. PubMed ID: 19298672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
    Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T
    Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case Report: Targeting of individual somatic tumor mutations by multipeptide vaccination tailored for HLA class I and II presentation induces strong CD4 and CD8 T-cell responses in a patient with metastatic castration sensitive prostate cancer.
    Zelba H; Rabsteyn A; Bartsch O; Kyzirakos C; Kayser S; Seibold M; Harter J; Latzer P; Hadaschik D; Battke F; Golf A; Rettig MB; Biskup S
    Front Immunol; 2023; 14():1271449. PubMed ID: 37920460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
    Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
    Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.
    Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H
    Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
    Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
    Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses.
    Herr W; Ranieri E; Olson W; Zarour H; Gesualdo L; Storkus WJ
    Blood; 2000 Sep; 96(5):1857-64. PubMed ID: 10961887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.
    Fehlings M; Jhunjhunwala S; Kowanetz M; O'Gorman WE; Hegde PS; Sumatoh H; Lee BH; Nardin A; Becht E; Flynn S; Ballinger M; Newell EW; Yadav M
    J Immunother Cancer; 2019 Sep; 7(1):249. PubMed ID: 31511069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.
    Sarivalasis A; Boudousquié C; Balint K; Stevenson BJ; Gannon PO; Iancu EM; Rossier L; Martin Lluesma S; Mathevet P; Sempoux C; Coukos G; Dafni U; Harari A; Bassani-Sternberg M; Kandalaft LE
    J Transl Med; 2019 Nov; 17(1):391. PubMed ID: 31771601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
    May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
    Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ
    J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Synthetic DNA, Multi-Neoantigen Vaccine Drives Predominately MHC Class I CD8
    Duperret EK; Perales-Puchalt A; Stoltz R; G H H; Mandloi N; Barlow J; Chaudhuri A; Sardesai NY; Weiner DB
    Cancer Immunol Res; 2019 Feb; 7(2):174-182. PubMed ID: 30679156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immune effects of specific CTLs response induced by dendritic cells pulsed with NY-ESO-1 peptide].
    Liu JW; Lu X; Yang ZM; Deng LJ; Yang L
    Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Oct; 49(5):840-846. PubMed ID: 29045966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adaptable antigen matrix platforms for peptide vaccination strategies and T cell-mediated anti-tumor immunity.
    Schetters STT; Li RJE; Kruijssen LJW; Engels S; Ambrosini M; Garcia-Vallejo JJ; Kalay H; Unger WWJ; van Kooyk Y
    Biomaterials; 2020 Dec; 262():120342. PubMed ID: 32905903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.